ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Short of Breath? It Could Be Interstitial Lung Disease

photo

SPONSORED CONTENT -- (StatePoint) It is estimated that about 250,000 Americans are living with idiopathic pulmonary fibrosis (IPF) and scleroderma associated ILD, two types of interstitial lung disease (ILD) that can make breathing difficult.

During September, which is Pulmonary Fibrosis Awareness Month, the American Lung Association, with support from Boehringer Ingelheim, is providing support and resources to those impacted by ILD. As part of the educational campaign, they are sharing these important facts and insights:

What is ILD? Interstitial lung disease is an umbrella term used for a large group of diseases that cause scarring (fibrosis) of the lungs. The scarring causes stiffness that makes it difficult to breathe and get oxygen to the bloodstream. Lung damage from ILDs is often irreversible and gets worse over time, however treatment is available to help relieve symptoms.

Who is at risk? While anyone can get interstitial lung disease, many things can increase the risk of ILD or even cause it, including genetics and certain medications or medical treatments, like radiation or chemotherapy. Smoking can not only cause ILDs, but can make the condition much worse, which is why anyone diagnosed is strongly encouraged to quit. Additionally, people with autoimmune diseases such as scleroderma -- also called systemic sclerosis -- are at an increased risk of developing an ILD. Unfortunately, in the case of idiopathic pulmonary fibrosis, the cause is unknown.

What are the symptoms of ILD? The most common symptom of all ILDs is shortness of breath. This is often accompanied by a dry cough, chest discomfort, fatigue and occasionally, weight loss.

How is ILD diagnosed? Healthcare providers test for ILD through a chest X-ray or CT scan. A lung function test may be used to measure total lung capacity, which may have deteriorated due to the ILD. In more serious cases, and to diagnose a specific type of ILD, more invasive procedures may be needed, such as a lung biopsy or bronchoscopy, which employs a small camera located at the end of a flexible tube that takes photos and collects tissue samples of the air passages.

How can ILD be managed? It is recommended that patients with idiopathic pulmonary fibrosis stay active and eat well. They may also be encouraged to use oxygen therapy as prescribed to help manage their condition. In some cases, the condition can be slowed by certain medications, and occasionally, people with IPF will be recommended for lung transplant.

Where can patients find support? Two new educational webcasts -- “Newly Diagnosed with ILD” and “Living with ILD” -- will provide education, resources and support to patients and their loved ones. Both webcasts will feature a healthcare provider and patient, and will be made available on-demand after the live showing. Critical resources can also be found through the American Lung Association’s Patient & Caregiver Network, a nationwide patient-centric community that connects people living with lung diseases like ILD with critical support, education and access to emerging research like clinical trials. Join for free at Lung.org/pcn. To learn more, call the Lung HelpLine at 800-LUNGUSA or visit Lung.org.

Understanding ILD and getting support is critical in helping patients breathe easier. Not only is diagnosis essential to disease treatment and management, connecting with others walking in the same shoes can be an invaluable source of support and practical help.

Photo Credit: (c) ljubaphoto / Getty Images

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.